Every 8-K that USANA Health Sciences Inc (USNA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow USNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full USNA filings page.
USANA Health Sciences reported fiscal Q2 2026 net sales of $223 million, down 5% year over year, and a net loss attributable to USANA of $(21.4) million versus prior-year net earnings of $9.7 million. Diluted EPS was $(1.16), including an estimated preliminary non-cash goodwill impairment charge of $29.1 million related to the Hiya reporting unit. Adjusted diluted EPS was $(0.07) compared with $0.74, and Adjusted EBITDA attributable to USANA was $27.8 million, down 9%.
The Core Nutritional segment generated net sales of $192 million, down 4%, with active customers declining 8% to 384,000. Hiya net sales were $28 million with active monthly subscribers down 17% to 166,000, while Rise Wellness delivered $3 million of net sales, up 40% year over year but sharply lower sequentially due to a packaging-related disruption.
Management reduced its fiscal 2026 outlook, now expecting consolidated net sales of $910 million, a net loss of $(11) million, adjusted diluted EPS of $0.76 and Adjusted EBITDA of $87 million, all below prior guidance ranges. The company ended Q2 with $169 million in cash and cash equivalents, no debt, and generated $20 million of free cash flow.
USANA Health Sciences reported the results of its Annual Meeting of Shareholders held on May 20, 2026. Shareholders representing 16,468,210 shares, about 89% of outstanding common stock, were present in person or by proxy, indicating strong participation.
All eight director nominees were elected, each receiving over 13.6 million votes in favor, with more than 2.1 million broker non-votes recorded for each seat. Shareholders also ratified the selection of KPMG LLP as independent registered public accounting firm for fiscal 2026, with 16,286,742 votes for.
On an advisory basis, shareholders approved the company’s executive compensation, with 13,811,489 votes for, 509,777 against, and 13,996 abstentions, along with 2,132,948 broker non-votes, signaling broad support for current pay practices.
USANA Health Sciences reported fiscal Q1 2026 net sales of $250.2 million, essentially flat year over year, while profitability declined. Net earnings were $7.5 million versus $9.4 million a year ago, and diluted EPS fell to $0.41 from $0.49. Adjusted diluted EPS was $0.61 compared with $0.73, and Adjusted EBITDA was $28.4 million versus $29.8 million.
The Core Nutritional segment generated $204 million in net sales, down 3% year over year but up 7% sequentially, with 404,000 active customers, a 12% annual decline yet 4% sequential growth. Hiya posted $32 million in net sales, down 13% year over year, while Rise Wellness net sales surged to $14 million, up 741% year over year.
USANA ended the quarter with $163 million in cash and $14 million of debt. Management reiterated full‑year 2026 guidance, including consolidated net sales of $925 million to $1.0 billion, net earnings of $20 million to $27 million, diluted EPS of $1.11 to $1.45, and Adjusted EBITDA of $101 million to $109 million.
USANA Health Sciences reported mixed 2025 results, with revenue up but profits down sharply. Fiscal 2025 net sales rose to $925.3 million from $854.5 million, but net earnings fell to $10.8 million from $42.0 million, and diluted EPS dropped to $0.58 from $2.19. Adjusted diluted EPS declined to $1.93 from $2.59, while Adjusted EBITDA slipped to $101.3 million from $110.3 million.
In Q4 2025, net sales were $226.2 million versus $213.6 million a year earlier, but the company posted a $1.8 million net loss, driven by a $7.0 million non‑cash impairment and $6.5 million of cost‑realignment charges, partly offset by a $3.2 million asset sale gain. Active customers in the core nutritional business declined to 387,000 from 454,000, while Hiya and Rise Wellness delivered strong growth.
For fiscal 2026, USANA guides to modest top-line growth and improved profitability. It projects consolidated net sales between $925 million and $1.0 billion, net earnings of $20.3–$26.6 million, diluted EPS of $1.11–$1.45, adjusted diluted EPS of $1.95–$2.29, and Adjusted EBITDA of $101.3–$109.3 million. The balance sheet shows $158 million of cash and $14 million of debt, after repurchasing 927,000 shares for $28 million in 2025.
USANA Health Sciences filed an amended report to detail compensation changes tied to its CEO transition. Former CEO Jim Brown will serve as a strategic advisor through December 31, 2026, receiving his $825,000 base salary, 2025 bonus, and standard employee benefits during this period.
After his advisory role ends, Brown is entitled to $1,500,000 in severance, paid in three $500,000 installments in 2027, 2028, and 2029, plus 18 months of company-paid COBRA benefits, in exchange for a release of claims and ongoing restrictive covenants. Unvested equity awards at separation will be cancelled.
Returning CEO Kevin Guest will receive an $850,000 base salary, a target annual bonus equal to 100% of salary, a 2026 RSU grant with a $1,700,000 grant date value, and standard benefit and savings plans. He also received a long-term performance award, payable in company shares after a four-year period ending January 1, 2030, if USANA’s stock delivers positive total shareholder return and outperforms the Russell 2000 Index by specified levels, with potential payouts from $850,000 up to $3,400,000.
USANA Health Sciences, Inc. reported that it has issued a press release with preliminary net sales for the full fiscal year ended January 3, 2026. The company also provided net sales guidance for its currently expected financial results for the fiscal year ending January 2, 2027. This information is furnished under Items 2.02 and 7.01 and is attached as Exhibit 99.1. The company states that this information is being furnished rather than filed under the Exchange Act and is not incorporated by reference into Securities Act registration statements.
USANA Health Sciences, Inc. reported a leadership transition in which Jim Brown has stepped down as Chief Executive Officer and President, effective January 8, 2026. He will remain with the company in an advisory role for a period at the discretion of the Board of Directors, providing some continuity during the change.
Kevin Guest, age 63, who currently serves as Executive Chairman of the Board and previously served as Chief Executive Officer, will reassume the role of Chief Executive Officer while continuing as Chairman. The company states there is no arrangement or understanding with any other person regarding his selection, and no family or related-party relationships requiring additional disclosure. The Compensation Committee has not yet determined the compensation arrangements for Mr. Brown’s separation or for Mr. Guest’s new role as Chief Executive Officer and expects to decide these shortly, after which an amendment will be filed. The company has issued a press release describing these changes.
USANA Health Sciences furnished an update on investor communications. The company announced a press release with financial results for the third quarter ended September 27, 2025, and said it will post a “Management Commentary” on its website. Executives will host a conference call with brief remarks followed by Q&A, with webcast and telephone access details provided.
The press release and Management Commentary are included as Exhibits 99.1 and 99.2 and are furnished, not filed. These materials will be available on www.usana.com.
USANA Health Sciences, Inc. filed a current report to let investors know it has released a press release with preliminary financial results for its third quarter ended September 27, 2025. The company is furnishing this information under the sections covering results of operations and Regulation FD, and it attaches the press release as Exhibit 99.1. The disclosure is classified as “furnished” rather than “filed,” which limits its use for certain legal purposes but still makes the preliminary quarterly results publicly available.